早期地塞米松治疗与重症COVID-19患者死亡率的相关性:法国多中心研究
该研究为法国13个ICU的观察性队列,纳入2020年连续收治的1058例COVID-19患者,其中611例(57.75%)接受早期地塞米松,358例(33.83%)未用任何类固醇,89例(8.41%)接受晚期地塞米松或其他类固醇。早期地塞米松组与无类固醇组的28天死亡率相似(15.06% vs 14.25%,P=0.59)。早期地塞米松与更少插管(48.55% vs 61.49%,P<0.001)和更多28天内无呼吸机天数(22 [2-28] vs 17 [1-28]天,P=0.003)相关,但呼吸机相关性肺炎更常见(HR 1.29 [1.01-1.63],P=0.04)。
要点
- 早期地塞米松与无类固醇组28天死亡率相似(15.06% vs 14.25%,P=0.59)。
- 早期地塞米松组插管比例低于无类固醇组(48.55% vs 61.49%,P<0.001)。
- 早期地塞米松组28天内无呼吸机天数多于无类固醇组(22 [2-28] vs 17 [1-28]天,P=0.003)。
- 早期地塞米松组呼吸机相关性肺炎风险高于无类固醇组(HR 1.29 [1.01-1.63],P=0.04)。
- 与28天死亡率相关的因素包括年龄较大(aHR 1.06,1.04-1.09,P<0.001)、SOFA评分更差(aHR 1.13,1.06-1.20,P<0.001)和免疫抑制状态(aHR 1.59,1.01-2.50,P=0.043)。
适用人群与场景
- 2020年入住法国13个ICU的连续COVID-19患者。
研究设计与关键结果
- 研究类型:观察性队列研究,法国13个ICU,纳入1058例连续COVID-19患者。
- 分组:早期地塞米松组611例(57.75%),无类固醇组358例(33.83%),晚期地塞米松或其他类固醇组89例(8.41%)。
- 主要终点:早期地塞米松组与无类固醇组28天死亡率相似(15.06% vs 14.25%,P=0.59)。
- 与28天死亡率相关的因素:年龄较大(aHR 1.06;1.04-1.09;P<0.001)、SOFA评分更差(aHR 1.13;1.06-1.20;P<0.001)、免疫抑制状态(aHR 1.59;1.01-2.50;P=0.043)。
- 次要终点:早期地塞米松组插管比例低于无类固醇组(48.55% vs 61.49%,P<0.001);28天内无呼吸机天数多于无类固醇组(22 [2-28] vs 17 [1-28]天,P=0.003)。
- 不良事件:早期地塞米松组呼吸机相关性肺炎(VAP)风险高于无类固醇组(HR 1.29 [1.01-1.63],P=0.04);血流感染、真菌感染或消化道出血无差异。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在重症COVID-19患者中,早期地塞米松未显示降低28天死亡率,但可能与更少插管和更多无呼吸机天数相关;接受有创机械通气的患者使用早期地塞米松可能与更高的VAP风险相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dexamethasone is recommended for COVID-19 patients who require oxygen therapy. However, its effectiveness in reducing mortality and intubation, and its safety, remain debated. We aimed to investigate whether dexamethasone reduces day-28 mortality in unselected patients with critical COVID-19.
METHODS: We performed an observational cohort study in consecutive COVID-19 patients admitted to any of 13 French intensive care units (ICUs) in 2020. The primary objective was to determine whether early dexamethasone therapy was associated with day-28 mortality and the secondary objectives were to assess whether early dexamethasone decreased intubation requirements and to collect adverse events.
RESULTS: Of 1058 included patients, 611 (57.75%) received early dexamethasone (early dexamethasone group), 358 (33.83%) did not receive any steroids (no steroids group), and 89 (8.41%) received late dexamethasone or other steroids. Day-28 mortality was similar between the early dexamethasone and the no steroids groups (15.06% and 14.25%, respectively; P = 0.59). Factors associated with day-28 mortality were older age (adjusted hazard ratio [aHR], 1.06; 1.04-1.09; P < 0.001), worse SOFA score (aHR, 1.13; 1.06-1.20; P < 0.001), and immunocompromised status (aHR, 1.59; 1.01-2.50; P = 0.043). Early dexamethasone was associated with fewer intubations (48.55% vs. 61.49%, P < 0.001) and more ventilator-free days by day 28 (22 [2-28] vs. 17 [1-28] days, P = 0.003), compared to no steroids. Ventilator-associated pneumonia (VAP) was more common with early dexamethasone (HR, 1.29 [1.01-1.63], P = 0.04) than with no steroids, whereas no differences were noted for bloodstream infection, fungal infection, or gastrointestinal bleeding.
CONCLUSIONS: Early dexamethasone in critically ill COVID-19 patients was not associated with lower day-28 mortality. However, early dexamethasone was associated with lower intubation needs and more ventilator-free days by day 28. In patients treated with invasive mechanical ventilation, early dexamethasone was associated with a higher risk of VAP.
参考来源
- Raymond M, Le Thuaut A, Asfar P, et al. Association of early dexamethasone therapy with mortality in critically Ill COVID-19 patients: a French multicenter study. Ann Intensive Care. 2022. PMID: 36308564. doi:10.1186/s13613-022-01074-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。